Back to PFEView full pipeline
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
3 competitors in Acute Myeloid Leukemia
View Full LandscapeDrug Information
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Regulatory Approvals
EMA6/26/2020
Daurismo
Daurismo is indicated, in combination with low-dose cytarabine, for the treatment of newly diagnosed de novo or secondary acute myeloid leukaemia (AML) in adult patients who are not candidates for standard induction chemotherapy.
Orphan
View on EMADrug Science
Mechanism of action & safety profile
Related Pipeline
13 valent pneumococcal conjugate vaccine with Polysorbate 80Phase 3
Vaccines, Pneumococcal
Insulin LisproPhase 3
Diabetes Mellitus
Cyclosporine APhase 3
Renal Transplantation
DVS-233 SR (desvenlafaxine sustained release )Phase 3
Major Depressive Disorder
MeropenemPhase 3
Complicated Intra-abdominal Infections
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts